Efficacy of Sodium-Glucose Cotransporter-2 inhibitors in heart failure patients treated with dual angiotensin receptor blocker-neprilysin inhibitor: An updated meta-analysis
| Autor: | Haider Kamal Khan, Fahd Niaz Shaikh, Farouk Mookadam, Muhammad Fahad Wasim, Naser Yamani, Saba Sarfraz, Samuel Unzek, Talal Almas, Anousheh Awais Paracha |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
Systematic Review / Meta-analysis
Angiotensin receptor medicine.medical_specialty Ejection fraction business.industry MEDLINE Sodium-Glucose Cotransporter-2 inhibitors Heart failure General Medicine medicine.disease Dual angiotensin receptor blocker-neprilysin inhibitor Meta-analysis Pooled analysis Internal medicine Sodium/Glucose Cotransporter 2 Medicine Surgery business Neprilysin |
| Zdroj: | Annals of Medicine and Surgery |
| ISSN: | 2049-0801 |
| Popis: | Background Recent data suggest that the prevalence of heart failure has increased to approximately 23 million people globally. With increasing advancement in pharmacotherapeutics, Sodium-Glucose Cotransporter-2 inhibitors (SGLT2i) have garnered attention among clinicians to treat Heart failure with reduced ejection fraction (HFrEF) in diabetic as well as non-diabetic patients. Methods MEDLINE, Scopus, Embase and Cochrane CENTRAL database were searched using relevant keywords and MeSH terms. Studies were considered only if they were randomized in nature and had a sample size >1000 HF patients. Results Our comprehensive search strategy yielded 864 articles, of which three RCTs met the inclusion criteria with a total population of 9696. Pooled analysis revealed an association between the use of SGLT2i and decreased frequency of primary outcome irrespective of background ARNI use (HR 0.73, 95% CI [0.58–0.93], p = 0.0106; HR 0.73, 95% CI [0.66–0.81], p Highlights • Heart failure (HF) prevalence has increased to approximately 23 million people globally. • With advancements in treatment strategies for HF patients, a novel drug class, SGLT2i has garnered attention among clinicians. • This meta-analysis collects the latest trial-based evidence and confirms the association between decreased frequency of primary outcome and SGLT2i use. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|